WINTON GROUP Ltd Invests $6.90 Million in Organon & Co. $OGN

WINTON GROUP Ltd acquired a new stake in shares of Organon & Co. (NYSE:OGN - Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 509,862 shares of the company's stock, valued at approximately $6,904,000. WINTON GROUP Ltd owned about 0.19% of Organon & Co. at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Allied Private Wealth LLC purchased a new stake in Organon & Co. in the second quarter valued at about $33,000. Eurizon Capital SGR S.p.A. purchased a new stake in shares of Organon & Co. during the fourth quarter worth about $44,000. Kestra Advisory Services LLC acquired a new position in shares of Organon & Co. during the fourth quarter valued at about $47,000. WNY Asset Management LLC purchased a new position in shares of Organon & Co. in the 1st quarter valued at approximately $64,000. Finally, Empowered Funds LLC acquired a new stake in Organon & Co. in the 4th quarter worth approximately $74,000. 77.43% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered shares of Organon & Co. from a "hold (c)" rating to a "hold (c-)" rating in a research note on Monday, August 3rd. Five equities research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Reduce" and a consensus price target of $11.40.

Organon & Co. Stock Performance

OGN opened at $13.69 on Thursday. The company has a current ratio of 1.95, a quick ratio of 1.44 and a debt-to-equity ratio of 8.43. Organon & Co. has a 12-month low of $5.69 and a 12-month high of $13.78. The firm has a 50 day moving average of $13.63 and a two-hundred day moving average of $11.47. The firm has a market capitalization of $3.59 billion, a PE ratio of 17.77, a P/E/G ratio of 1.27 and a beta of 1.52.

Organon & Co. Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be issued a $0.02 dividend. This represents a $0.08 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Organon & Co.'s dividend payout ratio is presently 10.39%.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.

Want to see what other hedge funds are holding OGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organon & Co. (NYSE:OGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.